Cepheid  

(Public, NASDAQ:CPHD)   Watch this stock  
Find more results for CPHD
38.23
-0.03 (-0.08%)
May 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.14 - 38.36
52 week 28.12 - 46.00
Open 37.95
Vol / Avg. 346,400.00/450,283.00
Mkt cap 2.57B
P/E     -
Div/yield     -
EPS -0.22
Shares 67.11M
Beta 1.20
Inst. own 101%
Jul 15, 2013
Q2 2013 Cepheid Earnings Release Add to calendar
May 14, 2013
Cepheid at Bank of America Merrill Lynch Health Care Conference
Apr 18, 2013
Q1 2013 Cepheid Earnings Conference Call
Apr 15, 2013
Q1 2013 Cepheid Earnings Release
Mar 6, 2013
Cepheid at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 0.34% -6.05%
Operating margin 0.35% -6.44%
EBITD margin - 5.85%
Return on average assets 0.37% -6.48%
Return on average equity 0.49% -8.73%
Employees 945 -
Carbon Disclosure Rating - -

Address

904 Caribbean Drive
SUNNYVALE, CA 94089
United States - Map
+1-408-5414191 (Phone)
+1-408-5414192 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Cepheid is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the Clinical market, as well as for application in its Non-Clinical biothreat, industrial and partner markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Its two principal systems are the GeneXpert and SmartCycler. The GeneXpert system, its primary offering in the Clinical market, integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors� offices. The SmartCycler system integrates DNA amplification and detection to allow analysis of a sample.

Officers and directors

John L. Bishop Chairman of the Board, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Andrew D. Miller Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Humberto Reyes Chief Operating Officer, Executive Vice President
Age: 67
Bio & Compensation  - Reuters
David H. Persing M.D., Ph.D. Executive Vice President, Chief Medical and Technology Officer, Director
Age: 57
Bio & Compensation  - Reuters
Joseph H. Smith Executive Vice President - Business Development, General Counsel
Age: 68
Bio & Compensation  - Reuters
Kerry J. Flom Ph.D. Executive Vice President, Chief Regulatory Officer
Age: 61
Bio & Compensation  - Reuters
Philippe Jacon Executive Vice President - International Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Warren C. Kocmond Jr. Executive Vice President - Global Operations
Age: 49
Bio & Compensation  - Reuters
Cristina H. Kepner Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 65
Bio & Compensation  - Reuters